ORLANDO (EGMN) – Beta-blockers appear to be cardioprotective in breast cancer patients on trastuzumab, according to a prospective case-control study. The risk of developing new-onset heart failure or left ventricular dysfunction during 1 year on trastuzumab (Herceptin) was 65% lower in 30 breast cancer patients who were incidentally on a beta-blocker at the start of the monoclonal antibody therapy than in 167 other breast cancer patients who were not, Thomas B. Cook, Ph.D., reported at the annual...